0000950170-24-032990.txt : 20240318
0000950170-24-032990.hdr.sgml : 20240318
20240318174514
ACCESSION NUMBER: 0000950170-24-032990
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240318
DATE AS OF CHANGE: 20240318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prasad Raju
CENTRAL INDEX KEY: 0001968317
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 24760328
MAIL ADDRESS:
STREET 1: CRISPR THERAPEUTICS, INC.
STREET 2: 105 W FIRST STREET
CITY: BOSTON
STATE: MA
ZIP: 02127
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2024-03-14
0001674416
CRISPR Therapeutics AG
CRSP
0001968317
Prasad Raju
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
false
true
false
false
Chief Financial Officer
false
Common Shares
2024-03-14
4
M
false
10000
A
10000
D
Common Shares
2024-03-15
4
S
false
3524
72.69
D
6476
D
Restricted Stock Units
2024-03-14
4
M
false
10000
D
Common Shares
10000
30000
D
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.
/s/ AJ Silver, attorney-in-fact
2024-03-18